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Abstract
Drug combinations are becoming a standard treatment of many complex diseases due to
their capability to overcome resistance to monotherapy. In the current preclinical drug com-
bination screening, the top combinations for further study are often selected based on syn-
ergy alone, without considering the combination efficacy and toxicity effects, even though
these are critical determinants for the clinical success of a therapy. To promote the prioritiza-
tion of drug combinations based on integrated analysis of synergy, efficacy and toxicity pro-
files, we implemented a web-based open-source tool, SynToxProfiler (Synergy-Toxicity-
Profiler). When applied to 20 anti-cancer drug combinations tested both in healthy control
and T-cell prolymphocytic leukemia (T-PLL) patient cells, as well as to 77 anti-viral drug
pairs tested in Huh7 liver cell line with and without Ebola virus infection, SynToxProfiler pri-
oritized as top hits those synergistic drug pairs that showed higher selective efficacy (differ-
ence between efficacy and toxicity), which offers an improved likelihood for clinical success.
Author summary
High-throughput combinatorial screening is an established approach to identify candidate
drug combinations to be further developed as safe and effective treatment options for
many diseases, such as various types of cancers, bacterial, malarial, and viral infections.
The selection of top performing drug combinations for further development is an impor-
tant step for the success of the screen, where not only the synergy but also selective efficacy
and potential toxicity of the drug pairs should be critically assessed. Currently, there is no
method available for this; therefore, we developed SynToxProfiler tool, which was demon-
strated in two different application cases to prioritize synergistic drug pairs with higher
efficacy and lower toxicity as top hits, providing thus an increased likelihood for their clin-
ical success.
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Introduction
High throughput screening (HTS) of approved and investigational agents in preclinical model
systems has been established as an efficient technique to identify candidate drug combinations
to be further developed as safe and effective treatment options for many diseases, such as HIV,
tuberculosis and various types of cancers [1, 2]. Currently, the selection of top combinations
for further development often relies merely on the observed synergy between drugs, while
neglecting their actual efficacy and potential toxic effects, that are the other key determinants
for the therapeutic success of drugs in the clinics [3]. Notably, around 20% of drugs fail in the
early development phase because of safety concerns (non-tolerated toxicity), and over 50% fail
due to lack of sufficient efficacy [4]. Further, a recent study argued that many clinically-used
anticancer combination therapies confer benefit simply due to patient-to-patient variability,
not because of drug additivity or synergy [3], indicating that even non-synergistic combina-
tions may be beneficial for therapeutic purposes if they have a high enough efficacy and low
enough toxicity profiles.
To make a better use of these various components of drug combination performance already
in the preclinical HTS experiments, we implemented, to the best of our knowledge, the first
web-tool, SynToxProfiler, which enables users to profile synergy, toxicity and efficacy of drug
combinations simultaneously for the top combination prioritization (Fig 1). For each drug pair,
SynToxProfiler calculates the total volume under the multi-dose combinatorial response sur-
face measured in the diseased and healthy cells, respectively, to quantify efficacy and toxicity
scores (S1 Fig). Further, synergy matrix is estimated from the dose-response matrix of the dis-
eased cells using an appropriate synergy model (e.g. Highest-single agent, Bliss, Loewe, or Zero
interaction potency model (ZIP)) [5–8], depending on the drugs and hypotheses of the HTS
experiment. The synergy score is calculated as the integrated volume under the estimated dose-
synergy matrix. Further, each combination is ranked based on its integrated synergy, toxicity
and efficacy scores. While the current implementation focuses on pairwise drug combinations,
the method is also extendable for higher-order (3 or more drugs) combination screening.
In this report, we demonstrate the use of SynToxProfiler as a systematic tool for the prioriti-
zation of top combinatorial hits both in T-cell prolymphocytic leukemia (T-PLL) and anti-
Ebola drug combination screening. The SynToxProfiler platform is implemented as an open-
source and interactive web-tool (https://syntoxprofiler.fimm.fi), which enables fast and fully-
automated top hit selections in HTS combination screening with 2D and 3D visualization (Fig
1, S2 Fig). To guarantee the replicability of the work and possibilities for further extension of
the tool by academic users, we have also provided the source code of the method at https://
github.com/IanevskiAleksandr/SynToxProfiler.
Results
SynToxProfiler prioritizes clinically useful drug combination for T-PLL
cancer patient and Ebola virus infection
To demonstrate the performance of SynToxProfiler in prioritizing therapeutically-relevant
synergistic combinations, we applied it to the in-house drug screening data involving 20
anti-cancer drug combinations tested in one control and one T-PLL patient-derived cells.
The application of SynToxProfiler to the T-PLL screen revealed that ranking of combina-
tions based on the STE score successfully prioritizes both effective and safe drug pairs. For
example, Cytarabine-Daunorubicin pair was identified as the top hit out of the tested combi-
nations (Table 1, S1 Data); this combination is widely used as approved induction therapy
for acute myeloid leukemia treatment [9]. Ibrutinib-Navitoclax was ranked as the third-best
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combination for further study; such combinations (Ibrutinib with Bcl2 inhibitors) have
shown promising results in phase II clinic trial (NCT02756897) for chronic lymphocytic
leukemia (CLL), and recently suggested as the first-line treatment for CLL [10].
To further illustrate the wide applicability of SynToxProfiler also in non-cancer combinato-
rial screens, we used a published dataset of 77 anti-viral agents, where the drug combinations
efficacy and toxicity were tested in Ebola-infected and non–virus-infected Huh7 liver cells,
respectively. SynToxProfiler ranked the established combinations (e.g. clomifene-sertraline
and sertraline-toremifene) that inhibit EBOV fusion to cell surface as top hits in the Ebola
combination screen (S2 Data). All the three drugs (clomifene, sertraline and toremifene) have
showed survival benefit in in-vivo murine Ebola virus infection model [11]. These two case
studies demonstrate that SynToxProfiler enables identification of both clinically established
drug pairs as top hits, as well as novel drug pairs with a translational potential.
Top hits selected by SynToxProfiler based on integrated scoring are
synergistic drug pairs with higher selective efficacy
We compared the synergy and selective efficacy levels of the top hits prioritized based either
on the STE score, synergy score or selective efficacy scores, using the 77 combinations in the
Ebola dataset [12]. The top combinations identified by STE scores had a notably higher selec-
tive efficacy as well as higher synergy (as shown by arrow in Fig 2A), indicating that STE score
represents a proper balance between high selective efficacy and synergy. Additionally, we
observed a marked overlap (65%) between the top-10% of analyzed combinations prioritized
Fig 1. A schematic overview of SynToxProfiler. The dose-response data from drug combination screening, measured in both diseased (e.g. patient-
derived cells) and healthy control cells (e.g. PBMCs), is provided as input to SynToxProfiler (left panel). Then, SynToxProfiler quantifies drug
combination efficacy and synergy (using combination responses in diseased cells) as well as toxicity (using combination responses in control cells) for
each drug pair (middle panel), and summarizes them into integrated synergy, toxicity and efficacy (STE) score. The increase in red color gradient in the
efficacy and toxicity matrix (middle panel) denotes an increase in percentage inhibition of cancer and healthy cells, respectively. The color gradient
from white to red in the synergy matrix shows the shift of drug interactions from antagonism to synergy. The STE score is further used to rank and
visualize the drug pairs in 2D or 3D interactive plots (right panel). The color gradient from blue to red in the right panel depicts an increasing STE score
from low to high.
https://doi.org/10.1371/journal.pcbi.1007604.g001
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based on STE score and synergy score, as well as based on the STE score and selective efficacy
score (50% overlap), as shown in Fig 2B. In contrast, there was a smaller overlap (41%)
between the top-10% hits selected based on selective efficacy and synergy scores. Further, a
low Pearson correlation (r = 0.22) between selective efficacy and synergy was observed. These
results indicate that synergy and selective efficacy are independent drug combination compo-
nents, which cannot be used alone to prioritize potent and less toxic synergistic drug
combinations.
A more detailed analysis revealed that SynToxProfiler ranks lower the toxic drug pairs
despite their higher synergy. For example, in the T-PLL case, SynToxProfiler ranks 9th the
combination of prexasertib-clofarabine, despite its higher synergy (4th, see Table 1), because of
its low efficacy and higher toxicity, as also observed in Philadelphia-negative B-/T-ALL cell
line model where addition of prexasertib increased the cytotoxicity of clofarabine [13]. Simi-
larly, SyntoxProfiler ranked clomiphene citrate and sertraline HCl combination (STE = 0.96)
as the top hit in the Ebola screen (Fig 3), despite its lower synergy as compared to more syner-
gistic toremifene citrate and apilimod pair (STE = 0.86). This is due to a higher toxicity of the
latter (13.30 vs 24.60), although both of the drug combinations have similar efficacy scores
(70.88 vs 68.20). The relative lower ranking of combinations involving cilchicine and apilimod
is in accordance with their observed extreme toxicity in the clinic [14,15]. These results indi-
cate that SynToxProfiler can identify safe top hits with high selective efficacy and synergy that
have increased potential for clinical success, as compared to hits selected based on synergy
alone.
Table 1. Ranking of 20 in-house measured combinations based on STE scores calculated from the most synergistic area of dose-response matrix in T-PLL and
healthy control cells.
Drug1 (concentration range in
nM)
Drug2 (concentration range in
nM)
Synergy score
(SAB)
Efficacy score
(EAB)
Toxicity score
(TAB)
Selective efficacy score
(EAB)
STE
score
Cytarabine (0–100) Daunorubicin (0–1000) 6.70 58.73 20.86 37.86 0.83
Trametinib (0–100) S-63845 (0–25) 4.20 2.00 12.43 35.97 0.83
Ibrutinib (0–1000) Navitoclax (0–100) 1.53 71.69 19.92 51.76 0.83
Quizartinib (0–100) S-63845 (0–100) 0.69 56.38 27.43 28.95 0.75
Omacetaxine (0–1000) Ipatasertib (0–1000) 0.19 70.10 11.36 58.74 0.73
Gefitinib (0–1000) Omacetaxine (0–1000) 0.69 69.36 17.07 52.28 0.73
Clofarabine (0–1000) Idarubicin (0–100) 2.08 73.88 27.53 46.35 0.73
Omacetaxine (0–1000) Alpelisib (0–1000) -0.72 70.87 10.95 59.92 0.68
Clofarabine (0–1000) Prexasertib (0–1000) 1.59 19.70 8.90 10.80 0.68
Gefitinib (0–25) Trametinib (0–1000) 0.40 10.25 4.51 5.74 0.55
Buparlisib (0–100) Ibrutinib (0–1000) 0.94 4.45 1.33 3.12 0.55
Ibrutinib (0–100) Doxorubicin (0–100) 0.84 9.82 1.73 8.09 0.53
Vinorelbine (0–1000) Clofarabine (0–1000) -1.14 66.46 21.40 45.06 0.50
Clofarabine (0–1000) Omacetaxine (0–1000) -4.27 20.34 0.59 19.75 0.38
Dexamethasone (0–1000) Clofarabine (0–1000) -16.37 0.00 0.00 0.00 0.35
Dasatinib (0–1000) Ipatasertib (0–100) 0.24 0.67 2.08 -1.41 0.25
Carboplatin (0–1000) Dexamethasone (0–1000) -0.51 0.00 0.00 0.00 0.20
Ipatasertib (0–1000) ASP3026 (0–1000) -0.01 0.00 0.00 0.00 0.18
Idarubicin (0–100) Ibrutinib (0–100) -0.89 0.69 2.28 -1.59 0.18
Trametinib (0–100) Dasatinib (0–25) -2.05 0.00 1.23 -1.23 0.10
Synergy scores were calculated using ZIP [8] model (default option in SynToxProfiler).
https://doi.org/10.1371/journal.pcbi.1007604.t001
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Fig 2. STE score considers both synergy and selective efficacy when prioritizing potent drug combinations. (A) 3D surface shows increase in STE
score with increasing synergy and selective efficacy scores across 77 antiviral combinations measured in Huh7 liver cell line infected with Ebola virus
(the arrow marks the gradient of the increase in STE score). The 3D surface is fitted by a generalized additive model with a tensor product smooth,
implemented in mgcv R package. The color gradient from blue to red represents the low to high STE score for drug combinations. (B) Scatter plot
showing the overlap in the top hits selected on the basis of STE and Synergy (red), STE and selective efficacy(orange), and selective efficacy and synergy
(blue) scores. The dotted vertical line denotes the overlap between the top 10% combinations selected based on any of the three scores.
https://doi.org/10.1371/journal.pcbi.1007604.g002
Fig 3. SynToxProfiler penalizes for toxicity of drug pairs while ranking top hits. The efficacy, toxicity, and synergy matrices for the top drug pairs
selected based on the highest STE score (clomiphene citrate and sertraline HCL, upper panel) and the highest synergy score (toremifene citrate and
apilimod, lower panel). The synergy was calculated using the ZIP model implemented in SynergyFinder [21]. The square with dotted line denotes the
3x3 concentration range with the most synergistic area in the dose-response matrix.
https://doi.org/10.1371/journal.pcbi.1007604.g003
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Comparison of SynToxProfiler and Combenefit using different synergy
scoring models
To benchmark the results of SynToxProfiler against other combination scoring methods,
we firstly compared the volume-based SynToxProfiler Bliss synergy calculation against the
widely-used SUM_SYN_ANT synergy score of Combenefit [16]. As expected, we observed a
strong correlation in both datasets (Pearson correlation of 0.92 and 0.83 for the 20 anti-cancer
and 77 anti-Ebola drug combinations, respectively) between the two methods (S3 Fig). We
also observed that the top combination hits selected by SynToxProfiler are highly overlapping
between different synergy models; for instance, 9 and 8 of the top-10 combinations identified
based on the STE score using ZIP synergy model are actually the same when using Bliss and
HSA models in T-PLL and anti-Ebola screening, respectively (S2 and S3 Tables).
Additionally, we compared the top hits from T-PLL screen ranked based on Combenefit
synergy score and STE score using Bliss synergy model, and observed that STE score helps to
deprioritize toxic and low efficacy drug pairs that would have been selected based on the Com-
benefit score. For example, Buparlisib-Ibrutinib combination was ranked 11th by SynToxProfi-
ler, although it has a higher Combenefit synergy rank (6th), because of its lower efficacy and
higher toxicity (S4 Table), similar to the observation made in Phase 1 clinical trials for hemato-
logical cancers (in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma,
and follicular lymphoma) [17]. Similarly, in the anti-Ebola data, SynToxProfiler ranks rela-
tively high (4th) colchicine/toremifenecitrate combination, despite its low synergy rank (18th)
given by Combenefit, because of its higher efficacy (S5 Table). This combination synergisti-
cally blocks Ebola infections as toremifenecitrate blocks its fusion with the cells and colchicine
blocks the trafficking to endolysosomes [12], indicating that SynToxProfiler prioritizes drug
pairs with a strong potential to be rapidly advanced towards clinical settings and used as thera-
peutic interventions.
Discussion
The primary motivation for the use of drug combinations in the clinical applications is to
achieve higher efficacy (by means of drug interactions), with reduced toxicity (by decreasing
the drug doses). Therefore, HTS screening aims to discover drug pairs that are more effective
than the individual single drugs when used alone, and at the same time show less toxicity for
the patients. Hence, the assessment of synergistic efficacy along with toxicity is critical for the
selection of candidate drug pairs for further study, as there exists a fundamental trade-off
between clinical efficacy and tolerable toxicity. In this work, we showed how SynToxProfiler
prioritized cytarabine-daunorubicin as the top drug pair out of 20 anticancer combinations
for T-PLL case study (Table 1), and clomifene-sertraline for Ebola case study (S2 Data). The
identification of such clinically established drug pairs as top hits suggests that ranking based
on all the three components helps to identify combinations that have more chances to succeed
in the clinical practice. Notable, these effective and safe combinations would have been other-
wise missed if combinations were selected merely based on their synergy scores.
To the best of our knowledge, there are currently no methods to provide the global view in
terms of synergy, efficacy and toxicity of drug pairs in an HTS setting. In this respect, SynTox-
Profiler offers an important advancement into the current practice for drug combination
selection, as it provides an easy-to-use platform for in-vitro or ex-vivo assessment of the three
critical aspects of drug combinations that are necessary for success in the clinical applications.
As default, SynToxProfiler calculates the efficacy, toxicity and synergy scores within the most
synergistic concentration window (3x3), which allow for the comparison of drugs at their
most beneficial concentration ranges in those combination screens where the primary aim is
SynToxProfiler: An interactive tool for drug combination selection
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to find most synergistic drug pairs. Furthermore, SynToxProfiler facilitates the identification
of therapeutic window range at which the drugs show the highest efficacy and lowest toxicity
by visualization of the dose-response surfaces. Since SynToxProfiler uses the normalized vol-
ume-based scoring for synergy, efficacy and toxicity levels (see Methods and S1 Text), the Syn-
ToxProfiler framework can be easily utilized to prioritize synergistic drug combinations with
high selective efficacy also for higher-order combination screening (3 or more drugs). Due to
the lack of tools and methodology available to analyze and interpret combined synergy, effi-
cacy and toxicity of multi-component drug combinations, SynToxProfiler will be valuable
resource for prioritization of such combinations.
However, we note that although for some drug classes the in vitro toxicity measurement
strongly corelates with the clinical toxicity, the toxicity measurements in cell lines may not
accurately capture clinical toxicity for all drug classes or toxicity phenotypes [18, 19]. Hence,
due to this technical limitation of in vitro toxicity assays, the selected combinations will need
to be further tested in animal models or clinical studies. We expect that SynToxProfiler will
become even more useful when toxicity measurements from biologically more relevant pre-
clinical models, such as induced pluripotent cells and organoids of non-diseased tissue of
patients, start to become available for high throughput screening [20]. However, filtering out
combinations with in vitro toxicity should lead to savings of both time and resources, as well
as to reduced animal and human suffering. SynToxprofiler can be used also to identify and
characterize synergistic drug pairs with high toxicity and low efficacy in order to understand
the underlying mechanism behind chemical toxicity using appropriate model system. We sug-
gest that user should also visualize the dose-response curves of individual drugs for selected
top hits, as well as the full dose-combination matrices for efficacy, toxicity and synergy esti-
mates, to confirm the efficacy/synergy/toxicity summary scores before selection of top hits for
further study. Further, we recommend that users should carefully choose the appropriate syn-
ergy model based on their underlying hypothesis behind drug interactions, as the different
synergy models come with distinct assumptions for the synergy calculation. For example, one
should use Loewe model when the assumption is that drugs act on the same target or binding
site through the same mechanism, and Bliss model in the opposite case, when the assumption
is that drugs in combination act independently through different mechanisms, but together
they can exceed their individual responses.
In conclusion, we have developed SynToxProfiler, an interactive tool for HTS combination
hit prioritization that ranks drug pairs based on their combined synergy, efficacy and toxicity
profiles, which can be implemented in any HTS drug combination screening project, either as
stand-alone tool or combined with other screening and scoring approaches. We showed how
this tool enables identification of clinically established drug pairs as top hits and many more
compound pairs with a translational potential. The validity of the tool will hopefully be dem-
onstrated as other scientists start using SynToxProfiler. We hope the screening community
will find the tool useful and we are happy to receive feedback on how to improve its options.
We foresee SynToxProfiler will allow for more unbiased and systematic means to evaluate the
pre-clinical potency of drug combinations toward safe and effective therapeutic applications.
Methods
SynToxProfiler workflow
The SynToxProfiler web-application is freely available at https://syntoxprofiler.fimm.fi,
together with example drug combination data, video tutorial and step-by-step user instruc-
tions. SynToxProfiler enables ranking of drug combinations based on integrated efficacy,
synergy and toxicity profiles (Fig 1). Therefore, for each drug combination, SynToxProfiler
SynToxProfiler: An interactive tool for drug combination selection
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first calculates a normalized volume under dose-response surface to quantify combination
efficacy based on dose–response measurements on diseased cells, e.g., patient-derived primary
cells (see S1 Fig). Then, the combination synergy between each drug pair is estimated using
one of the synergy scoring models: Highest Single-Agent [5], Bliss independence [6], Loewe
additivity [7], or Zero Interaction Potency (ZIP) [8], as implemented in the SynergyFinder
webtool [21]. Normalized volume under the dose-synergy surface is utilized to quantify final
combination synergy score (S1 Fig). Next, using the measurements on control cells, if avail-
able, the normalized volume under dose–response matrix is calculated to estimate combina-
tion toxicity (S1 Fig). Finally, SynToxProfiler ranks the drug combinations based on integrated
combination synergy, toxicity and efficacy (STE) score. Alternatively, if measurement on con-
trol cells are not available, then the ranking of drug pairs can also be done based merely on
combination synergy and efficacy. As a result of the integrative analysis, SynToxProfiler pro-
vides a web-based exportable report, which allows users to interactively explore their results
(Fig 1 and S2 Fig). An interactive example of web-based report is given at https://syntoxprofiler.
fimm.fi/example. A more detailed description of the calculations and workflow with real exam-
ples is provided in the technical documentation, https://syntoxprofiler.fimm.fi/howto.
Calculation of normalized volume
The normalized volume under the dose-response surface is calculated while quantifying
combination efficacy and toxicity based on measurements on diseased and control cells,
respectively (S1 Fig). Synergy score is calculated based on measurements on diseased cells
as normalized volume under synergy matrix (excess matrix of combination responses over
expected responses determined by one of the synergy models, such as Bliss). For each combi-
nation AB of two drugs, A and B, the normalized volume under the dose-response surface for
efficacy (EAB), toxicity (TAB) and synergy (SAB) is calculated as:
EAB ¼
PCAmax
x¼CAmin
PCBmax
y¼CBmin
Eðx; yÞDcADcB
lnðCAmax=C
A
minÞ lnðC
B
max=C
B
minÞ
: ð1Þ
TAB ¼
PCAmax
x¼CAmin
PCBmax
y¼CBmin
Tðx; yÞDcADcB
lnðCAmax=C
A
minÞ lnðC
B
max=C
B
minÞ
: ð2Þ
SAB ¼
PCAmax
x¼CAmin
PCBmax
y¼CBmin
Sðx; yÞDcADcB
lnðCAmax=C
A
minÞ lnðC
B
max=C
B
minÞ
: ð3Þ
Here, cAmin and c
A
max are the minimum and maximum tested concentrations of drug
A, respectively, and cBmin, and c
B
max are those of drug B; Δc
A and ΔcB are the logarithmic
increase in concentration of drug A and drug B between two consecutive measurements of
dose-response matrix; and E(x, y), T(x, y) and S(x, y) are the efficacy, toxicity and synergy
levels respectively at concentration x of drug A and concentration y of drug B. The current
approach for volume-based scoring normalizes for the potentially different dose-ranges
measured in different drug combinations, as commonly occurring in HTS settings. The
extension of formulation for volume -based scoring of synergy, efficacy and toxicity profiles
for multi-drug combinations (3 or more drugs) is given in the S1 Text. We have also pro-
vided a step-by-step example of the calculation of STE score in a real example case as S4 Fig.
The efficacy, toxicity and synergy scores represent the summarized efficacy, toxicity and syn-
ergy level for a drug pair summarized over multiple concentration pairs (e.g. 8x8 dose-matrix
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design), where each combination is measured in a particular patient sample or cell line. A
higher STE score represents higher efficacy, higher synergy and lower toxicity of a drug pair.
Ranking of drug combinations
SynToxProfiler ranks the drug combinations based on an integrative analysis of synergy, toxic-
ity and efficacy, quantified as STE score (an example is given in S4 Fig). First, the difference in
efficacy (EAB) and toxicity scores (TAB) is calculated for each drug combination to quantify a
selective response in diseased cells, relative to that of control cells. We defined this difference
as a selective efficacy score (sEAB) of a drug combination, calculated by the difference of Eqs
(2) and (3). This theoretical concept for selective efficacy has been adopted from the single
drug dose-response assays, where the difference in normalized area under the curve (AUC)
between diseased and healthy cells is often used to calculate the patient-specific drug efficacies
[22, 23]. The final STE score is given by averaging two different ranks of (i) combination syn-
ergy score (SAB) (the higher is the synergy, the higher is the rank), and (ii) selective combina-
tion efficacy (sEAB) (the higher is selective efficacy, the higher is the rank):
STEAB ¼
rankðSABÞ þ rankðsEABÞ
2N
; ð4Þ
where SAB and sEAB are the synergy and selective efficacy scores, respectively, for a combina-
tion of drug A and B, calculated using the normalized volume under the dose-response surface;
and N is the total number of drug combinations being tested. However, since calculation of
STE score using the whole dose-response matrix may miss some of the top hit drug combina-
tions with a narrow synergistic dose window, SynToxProfiler also offers the users a possibility
to rank combinations based on the selective efficacy and synergy scores calculated only at the
most synergistic area of the drug combination matrix (defined as the 3x3 concentration win-
dow with the highest synergy in the dose-response matrix), instead of the default full matrix
calculation. The user guide of the tool along with step-by-step example and source code are
freely available at https://github.com/IanevskiAleksandr/SynToxProfiler.
Data submission and reporting
The default input of SynToxProfiler is a text or xlsx file that comprises annotations of each
drug combination dose–response matrix, including drug names, concentrations, cell types
(e.g. sample or control), and phenotypic responses (e.g. relative inhibition). The number of
drug combinations provided in the input file is unrestricted. More information on the input
file format is given in the user documentation (https://syntoxprofiler.fimm.fi/howto/). As the
result, SynToxProfiler provides an interactive visualization of STE scores using bar charts, as
well as 2- and 3-dimensional scatter plots. Publication-quality figures (e.g. heatmap for dose-
response and synergy matrix, 2D and 3D scatter plot for different scores) can be exported in
PDF files, and all the calculated scores can be downloaded in an xlsx file.
Ethics statement
The study has been approved by the ethics committee of the University of Helsinki. Peripheral
blood mononuclear cells (PBMCs) of a patient with T-cell prolymphocytic leukemia (T-PLL)
and a healthy volunteer were used in accordance with the regulations of Finnish Hematologi-
cal Registry and biobank (FHRB). The written informed consents were obtained from both
participants and the study was carried in accordance with the principles of Helsinki
declarations.
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Drug combination assay cases
The in-house drug combination testing was carried out at Institute for Molecular Medicine
Finland (FIMM). Peripheral blood mononuclear cells (PBMCs) of a patient with T-cell pro-
lymphocytic leukemia (T-PLL) and a healthy volunteer were used in accordance with the
regulations of Finnish Hematological Registry and biobank (FHRB). The written informed
consents were obtained from both participants and the study was carried in accordance with
the principles of Helsinki declarations. Twenty combinations of drugs with different mecha-
nisms of actions (see S1 Table) were tested on the PBMCs in 8x8 dose-response matrix assay
as described previously [24, 25]. Briefly, drugs were transferred on clear bottom 384-well
plates (Corning #3712) using an Echo 550 Liquid Handler (Labcyte) and dissolved in 5μl of
Mononuclear Cell Medium (PromoCell, C-28030) dispensed in each well using a MultiFlo
FX dispenser (BioTek). After that, 10 000 cells/ 20ul of Mononuclear Cell Medium were dis-
penced in each well of the plate. The concentration ranges were selected for each compound
separately to investigate the full dynamic range of dose-response relationships. After 72
hours incubation at 37˚C and 5% CO2, cell viability of each well was measured using the
CellTiter-Glo luminescent assay (Promega) and a Pherastar FS (BMG Labtech) plate reader.
As positive (total killing) and negative (non-effective) controls, we used 100 μM benzetho-
nium chloride and 0.1% dimethyl sulfoxide (DMSO), respectively, for calculating the relative
efficacy (% inhibition).
The published dataset of 78 antiviral drug combinations was tested at the Integrated
Research Facility, National Institutes of Allergy and Infectious Diseases (NIAID), in the
Huh7 liver cells infected with Makona isolate, Ebola virus/H.sapiens-tc/GIN/14/WPG-C05,
as described in the original study [14] (data available at https://matrix.ncats.nih.gov/matrix-
client/rest/matrix/blocks/6323/table and https://matrix.ncats.nih.gov/matrix-client/rest/
matrix/blocks/6324/table). Briefly, drugs in 50-μL of Dulbecco’s modified Eagle’s medium
were transferred to the Huh7 cells seeded in black, clear-bottomed, 96-well plates 1 hour prior
to inoculation with EBOV/Mak. After 48 hours of viral inoculation, drug combination efficacy
was measured in triplicates with a 6 × 6 dose-response matrix design using CellTiter-Glo
assays (Promega). The EBOV/Mak virus was detected using mouse antiEBOV VP40 antibody.
For the toxicity measurements, the same CellTiter-Glo assay was performed on non–virus-
infected Huh7 cells with 3 replicates for each drug concentration, and the assay was repeated
at least twice for confirmation. We utilized 77 out of the 78 combinations for the present analy-
sis; colchicine-colchicine pair was removed because the inhibition levels were 100% for all the
tested concentrations of this drug combination.
Supporting information
S1 Fig. Quantification of efficacy and toxicity in SynToxProfiler. A schematic representa-
tion of calculation of combination efficacy, synergy and toxicity based on dose–response mea-
surements on diseased cells or control cells. E(x,y) is the response at concentrations x and y of
drugs A and B, respectively; ΔcA and ΔcB are the logarithmic increase in concentration of drug
A and drug B between two consecutive measurements of the dose-response matrix.
(TIF)
S2 Fig. Two-dimensional visualization in SynToxProfiler. Scatter plot showing the distribu-
tion of a synergy score (x-axis) and selected efficacy score (y-axis) for 77 combinations tested
in the Ebola infected and non–virus-infected Huh7 liver cells. Each drug combination is col-
ored according to its STE score. Users can hover over the combinations to visualize their indi-
vidual scores (e.g. STE score, or combination synergy, efficacy and toxicity scores), along with
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different dose-response matrices (synergy, toxicity, and efficacy), separately for each drug
combination as shown here for the apilimod- toremifene citrate combination (right panel).
(TIF)
S3 Fig. The correlation between Bliss synergy scores calculated using SynToxProfiler and
Combenefit for full matrix in T-PLL (left panel) and anti-Ebola (right) drug combination
screening. The pearson (R) and Spearman (ρ) correlation coefficients for each data along with
respective correlation p-values are shown for both screens. The grey shaded area represents
the 95% confidence interval for the fitted regression lines. For calculation of Combenefit syn-
ergy score, we have used the SUM_SYN_ANT score.
(TIF)
S4 Fig. A step-by-step example of synergy, efficacy and toxicity (STE) score calculation
from dose–response measurements on diseased and control cells. The user can choose
whether the scores are calculated over the full dose-combination matrix, or over the most syn-
ergistic 3x3 dose window (the dotted square).
(TIF)
S1 Table. List of drugs used in the assay and their mechanism of action.
(DOCX)
S2 Table. Comparison of ranks of 20 anti-cancer drug combinations using SynToxProfiler
with ZIP, HSA and Bliss synergy models. The STE score and respective ranks has been calcu-
lated for most synergistic area in each combination under ZIP synergy model.
(DOCX)
S3 Table. Comparison of ranks of 77 anti-Ebola drug combinations using SynToxProfiler
with ZIP, HSA and Bliss synergy models. The STE score and respective ranks has been calcu-
lated for most synergistic area in each combination under ZIP synergy model.
(DOCX)
S4 Table. Comparison of ranks of T-PLL drug combinations using STE scores from Syn-
ToxProfiler and synergy score from Combenefit. The rank of Bliss synergy and STE scores
calculated for full synergy matrix by SynToxProfiler have been compared against SUM_SY-
N_ANT synergy score from Combenefit.
(DOCX)
S5 Table. Comparison of ranks of 77 anti-Ebola drug combinations using STE scores from
SynToxProfiler and synergy score from Combenefit. The rank of Bliss synergy and STE
scores calculated for full synergy matrix by SynToxProfiler have been compared against
SUM_SYN_ANT synergy score from Combenefit.
(DOCX)
S1 Data. Summary table for 20 anti-cancer drug combinations measured in 1 T-PLL sam-
ple and 1 healthy control analyzed using SynToxProfiler.
(XLSX)
S2 Data. Summary table for 77 anti-Ebola drug combinations measured in Huh7 cells with
and without viral infection and analyzed using SynToxProfiler.
(XLSX)
S1 Text. Text describing extension of the method for higher-order combinations.
(DOCX)
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